WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H584861
CAS#: 123424-57-7
Description: NO 756 is a D1 dopamine receptor antagonist.
Hodoodo Cat#: H584861
Name: NO 756
CAS#: 123424-57-7
Chemical Formula: C19H20ClNO
Exact Mass: 313.12
Molecular Weight: 313.825
Elemental Analysis: C, 72.72; H, 6.42; Cl, 11.30; N, 4.46; O, 5.10
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: NO 756; NO-756
IUPAC/Chemical Name: 8-Chloro-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
InChi Key: MAUFEMWATYGIAF-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H20ClNO/c1-21-9-7-14-11-15(20)5-6-16(14)18(12-21)17-4-2-3-13-8-10-22-19(13)17/h2-6,11,18H,7-10,12H2,1H3
SMILES Code: CN1CCC2=CC(Cl)=CC=C2C(C3=C(OCC4)C4=CC=C3)C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 313.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Criswell HE, Mueller RA, Breese GR. Pharmacologic evaluation of SCH-39166, A-69024, NO-0756, and SCH-23390 in neonatal-6-OHDA-lesioned rats. Further evidence that self-mutilatory behavior induced by L-dopa is related to D1 dopamine receptors. Neuropsychopharmacology. 1992 Sep;7(2):95-103. PubMed PMID: 1418306.
2: Sandeep S, Utsuk D. Level of knowledge regarding hepatitis-B immunization amongst health personnel in Delhi, India. J Commun Dis. 2010 Jun;42(2):147-51. PubMed PMID: 22471174.
3: Daly SA, Waddington JL. Two directions of dopamine D1/D2 receptor interaction in studies of behavioural regulation: a finding generic to four new, selective dopamine D1 receptor antagonists. Eur J Pharmacol. 1992 Mar 24;213(2):251-8. PubMed PMID: 1387846.